Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H2 2016, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.
Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands, fever and chills. Treatment includes antibiotics and healthy lifestyle.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tularaemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tularaemia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 2 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.Tularaemia.
Tularaemia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Tularaemia (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tularaemia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tularaemia (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tularaemia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tularaemia (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tularaemia (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tularaemia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Aradigm Corp
Arno Therapeutics Inc
DynPort Vaccine Company LLC
Emergent BioSolutions Inc
EpiVax Inc
Grifols SA
Merck & Co Inc
Tetraphase Pharmaceuticals Inc
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Tularaemia Overview 7
Therapeutics Development 8
Pipeline Products for Tularaemia - Overview 8
Pipeline Products for Tularaemia - Comparative Analysis 9
Tularaemia - Therapeutics under Development by Companies 10
Tularaemia - Therapeutics under Investigation by Universities/Institutes 11
Tularaemia - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Tularaemia - Products under Development by Companies 14
Tularaemia - Products under Investigation by Universities/Institutes 15
Tularaemia - Companies Involved in Therapeutics Development 16
Aradigm Corp 16
Arno Therapeutics Inc 17
DynPort Vaccine Company LLC 18
Emergent BioSolutions Inc 19
EpiVax Inc 20
Grifols SA 21
Merck & Co Inc 22
Tetraphase Pharmaceuticals Inc 23
Tularaemia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
AR-12 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ARD-3100 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ARD-3150 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
ciprofloxacin hydrochloride - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
EV-035 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Small Molecules for Infectious Diseases - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
solithromycin - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
SRI-011225 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
TP-271 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
tularaemia [strain A] vaccine - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
tularaemia [strain B] vaccine - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
tularaemia vaccine - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
tularemia vaccine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Tularaemia - Dormant Projects 69
Tularaemia - Discontinued Products 70
Tularaemia - Product Development Milestones 71
Featured News & Press Releases 71
Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 71
May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 72
Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases 72
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75
List of Tables
Number of Products under Development for Tularaemia, H2 2016 8
Number of Products under Development for Tularaemia - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Tularaemia - Pipeline by Aradigm Corp, H2 2016 16
Tularaemia - Pipeline by Arno Therapeutics Inc, H2 2016 17
Tularaemia - Pipeline by DynPort Vaccine Company LLC, H2 2016 18
Tularaemia - Pipeline by Emergent BioSolutions Inc, H2 2016 19
Tularaemia - Pipeline by EpiVax Inc, H2 2016 20
Tularaemia - Pipeline by Grifols SA, H2 2016 21
Tularaemia - Pipeline by Merck & Co Inc, H2 2016 22
Tularaemia - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Tularaemia - Dormant Projects, H2 2016 69
Tularaemia - Discontinued Products, H2 2016 70
List of Figures
Number of Products under Development for Tularaemia, H2 2016 8
Number of Products under Development for Tularaemia - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Top 10 Targets, H2 2016 25
Number of Products by Stage and Top 10 Targets, H2 2016 25
Number of Products by Top 10 Mechanism of Actions, H2 2016 27
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 27
Number of Products by Routes of Administration, H2 2016 29
Number of Products by Stage and Routes of Administration, H2 2016 29
Number of Products by Molecule Types, H2 2016 31
Number of Products by Stage and Molecule Types, H2 2016 31
